EndoBarrier Is A Non-Surgical, Reversible And Relatively Easy Approach

Scientists say that the ‘EndoBarrier Gastrointestinal Liner’ or the ‘Duodenojejunal Bypass Sleeve’ (DJBS) represents a good alternative to bariatric surgery. This is a minimally invasive procedure which avoids surgical incisions. It is also a reversible procedure which means that the device can be removed when and where needed. This procedure targets duodenum (upper part of small intestine) and prevents the contact of food with the digestive enzymes in the duodenum. A major share of calorie absorption occurs in this part of the small intestine. When a physical barrier is placed in this part, it interferes with the nutrients absorption. This markedly reduces the blood glucose level. Studies have proved that implantation of the impermeable sleeve in the duodenum causes a significant reduction in glycated hemoglobin (HbA1c), the most sensitive marker of a patient’s blood glucose level and a hallmark of diabetes.

How does the EndoBarrier work?

This gastrointestinal liner is a tube with open ends. It is y placed in the duodenum with a help of special device, endoscope. Small spikes on the outer wall of this tube grasp the intestinal wall and anchor the device to the intestine. Food passes through the stomach into the duodenum, enters this tube, passes mostly undigested through it, and reaches the jejunum, the second part of small intestine. The digestive enzymes that are secreted into the intestine flow down between the intestinal wall and the tube. The food is eventually acted upon by the digestive enzymes when they reach the jejunum. The device can be placed through the mouth and it can be endoscopically removed when needed. 

Studies suggest the EndoBarrier can improve glycemic control, marked by reductions in HbA1c levels, indicating better long-term blood sugar management. Some patients have even reduced or discontinued diabetes medications.

Studies also show rapid reduction in blood sugar levels with no significant change in insulin levels, supporting the fact that EndoBarrier improves insulin sensitivity.

See Also: Dietary Treatment Of Type 2 Diabetes Mellitus - Effectiveness Of Nuts

The device is already in use in Europe, Australia and South America for treatment of obese type-2 diabetes patients and it is currently under trial in the United States. So far, studies have given promising results in reducing weight, diabetes remission and reducing risk of heart diseases with a few adverse effects like nausea, vomiting and abdominal pain. 

Like all medical interventions, the EndoBarrier has potential side effects and risks. Some individuals have experienced gastrointestinal symptoms, such as nausea, vomiting, or abdominal pain. There have also been reports of device migration, malnutrition, and liver abscesses.

The EndoBarrier is typically designed for temporary placement (up to 12 months) and then removed. It's not a permanent solution, and researchers are still studying the long-term effects and benefits of the device.